A positive BRAF (V600E) has the potential to be cancerous, but it is not definitive and needs to be combined with other tests to make a definitive diagnosis. There are many types of mutations in the BRAF gene, the most common being the V600E mutation, which is the replacement of thymine by adenine at position 1799 in exon 15, and the replacement of lysine (V) by glutamic acid (E) at position 600 in the protein product, or V600E. The V600E mutation in the BRAF gene is associated with a variety of malignant tumors, including thyroid cancer, melanoma, non-small cell lung cancer, and colorectal cancer, and more than 60% of patients with thyroid cancer and about 10% of patients with colorectal cancer have BRAF (V600E) mutations. Therefore, BRAF (V600E) can be used as one of the diagnostic and differential diagnostic bases for colorectal cancer, thyroid cancer and other malignant tumors. Generally, BRAF (V600E)-positive patients are likely to suffer from malignant tumors such as papillary thyroid cancer, colorectal cancer, etc. However, there are also a few benign diseases that are BRAF (V600E)-positive, such as a few benign thyroid cancer nodules that are V600E-positive. Currently, BRAF (V600E) needs to be combined with other tests such as imaging and puncture biopsy for the diagnosis of malignant tumors, so it is recommended that patients should consult the doctor in time and make a comprehensive judgment by combining the results of other tests.